Ovarian and Uterine Carcinosarcomas: A Comparative Analysis of Prognostic Variables and Survival Outcomes

Introduction: Carcinosarcomas (malignant mixed Mullerian tumor) of the female genital tract are rare tumors associated with poor outcome. The objective of this study was to identify site-specific differences by comparing carcinosarcomas originating in the uterus and the ovaries. Methods: Data on patients with uterine and ovarian carcinosarcomas were extracted from the Surveillance, Epidemiology, and End Results database between 1988 and 2005. Kaplan-Meier log rank and Cox proportional hazards models were used for survival analysis and for identification of possible predictors for survival. Results: The identified cohort included 3683 women of whom 2759 (75%) have uterine carcinosarcoma and 924 (25%) have ovarian carcinosarcomas. The patients with uterine carcinosarcoma were older than the patients with ovarian carcinosarcoma (median age, 67 vs 65 years; P < 0.001). The women with uterine carcinosarcoma compared with those with ovarian carcinosarcoma were more often African American (17.3% vs 6%; P < 0.001) and presented more often with localized disease (47% vs 10.8%; P < 0.001). Uterine carcinosarcoma compared with ovarian carcinosarcoma differed significantly with regard to the performance of lymphadenectomy (62.6% vs 41.2%; P < 0.001) and the administration of radiotherapy (38.2% vs 4.8%; P < 0.001). When controlled for the extent of disease spread, uterine carcinosarcoma had a more aggressive clinical course and shorter survival compared with ovarian carcinosarcoma. Although age (P < 0.001), race (P = 0.01), stage (P < 0.001), lymphadenectomy (P < 0.001), and radiation (P < 0.001) were all significant prognostic factors in uterine carcinosarcoma, only age (P < 0.001), stage (P < 0.001), and lymphadenectomy (P < 0.001) were significant predictors in ovarian carcinosarcoma. Conclusion: Although uterine carcinosarcoma presents at an earlier stage than ovarian carcinosarcoma, it has a worse prognosis compared with ovarian carcinosarcoma, with a similar extent of disease spread. Improved survival observed in lymphadenectomy group lends support to its routine performance in patients with uterine and ovarian carcinosarcomas.

[1]  L. Cantrell,et al.  Carcinosarcoma of the Ovary: A Review , 2009, Obstetrical & gynecological survey.

[2]  A. Lopes,et al.  Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. , 2009, European journal of obstetrics, gynecology, and reproductive biology.

[3]  Jason D. Wright,et al.  The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. , 2008, American journal of obstetrics and gynecology.

[4]  A. Iasonos,et al.  A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. , 2008, Gynecologic oncology.

[5]  N. Mitra,et al.  Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. , 2008, Gynecologic oncology.

[6]  D. Gaffney,et al.  The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  V. Seshan,et al.  Uterine Carcinosarcomas and Grade 3 Endometrioid Cancers: Evidence for Distinct Tumor Behavior , 2008, Obstetrics and gynecology.

[8]  J. Diebold,et al.  Molecular genetic aberrations of ovarian and uterine carcinosarcomas—a CGH and FISH study , 2008, Virchows Archiv.

[9]  J. Wolf,et al.  A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. , 2007, Gynecologic oncology.

[10]  G. Mor,et al.  Carcinosarcoma of the ovary , 2007, International Journal of Gynecologic Cancer.

[11]  S. Temkin,et al.  Early-stage carcinosarcoma of the uterus: the significance of lymph node count , 2006, International Journal of Gynecologic Cancer.

[12]  L. Downs,et al.  Clinical features and outcomes of uterine and ovarian carcinosarcoma. , 2006, Gynecologic oncology.

[13]  J. Boyd,et al.  Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer , 2005, Clinical Cancer Research.

[14]  J. Thigpen,et al.  Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.

[15]  M. Zhan,et al.  Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. , 2004, Gynecologic oncology.

[16]  G. Jayson,et al.  Carcinosarcoma of the ovary , 2003, British Journal of Cancer.

[17]  E. Oliva,et al.  Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary. , 2002, Gynecologic oncology.

[18]  N. Hacker,et al.  Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus , 2001, Cancer.

[19]  B. Monk,et al.  Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus , 2000, Cancer.

[20]  R. Caduff,et al.  Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. , 1998, The American journal of surgical pathology.

[21]  A. Gadducci,et al.  Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. , 1997, Gynecologic oncology.

[22]  N. Weiss,et al.  The epidemiology of sarcomas of the uterus. , 1986, Journal of the National Cancer Institute.

[23]  E. Topuz,et al.  Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. , 2008, Gynecologic oncology.

[24]  M. Dimopoulos,et al.  Clinicopathological features of ovarian carcinosarcomas: a single institution experience. , 2005, Gynecologic oncology.